Skip to main
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. presents a promising outlook primarily due to its innovative therapies, particularly CRB-701, which is positioned to address unmet medical needs in oncology through its differentiated safety and efficacy profiles. Key Opinion Leaders (KOLs) emphasize the drug's favorable dosing schedule and its potential for combination therapies, which may expand its market reach beyond current indications. Additionally, the company's enhanced trial design and strong enrollment metrics suggest a high likelihood of meeting regulatory deadlines, thereby increasing its probability of success in subsequent developmental phases.

Bears say

Corbus Pharmaceuticals Holdings Inc faces significant risks that contribute to a negative outlook for its stock due to the inherent uncertainties in clinical trials and regulatory processes. The company’s product pipeline, including CRB-701 and CRB-913, may experience failures in demonstrating efficacy or safety, which could hinder their development and market approval. Additionally, the potential for commercial challenges from existing and emerging therapies, along with the possibility of delays in regulatory approval, poses further threats to the company’s viability and overall financial performance.

CRBP has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 5 analysts, CRBP has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.